140 related articles for article (PubMed ID: 29567399)
1. The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.
Moschetti V; Kim M; Sand M; Wunderlich G; Andersen G; Feifel U; Jang IJ; Timmer W; Rosenbrock H; Boland K
Eur Neuropsychopharmacol; 2018 May; 28(5):643-655. PubMed ID: 29567399
[TBL] [Abstract][Full Text] [Related]
2. First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males.
Moschetti V; Boland K; Feifel U; Hoch A; Zimdahl-Gelling H; Sand M
Br J Clin Pharmacol; 2016 Nov; 82(5):1315-1324. PubMed ID: 27378314
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Miyoshi S; Krishnaswami S; Toyoizumi S; Nakamura H; Zwillich SH
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):11-20. PubMed ID: 31713350
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
Zhao X; Wang Z; Wang Y; Zhang H; Blode H; Yoshikawa K; Becker C; Unger S; Frey R; Cui Y
Clin Pharmacokinet; 2016 May; 55(5):615-24. PubMed ID: 26507720
[TBL] [Abstract][Full Text] [Related]
5. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
[TBL] [Abstract][Full Text] [Related]
6. Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.
Moschetti V; Schlecker C; Wind S; Goetz S; Schmitt H; Schultz A; Liesenfeld KH; Wunderlich G; Desch M
Clin Drug Investig; 2018 Aug; 38(8):737-750. PubMed ID: 29846887
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
Kim BH; Lim HS; Chung JY; Kim JR; Lim KS; Sohn DR; Cho JY; Yu KS; Shin SG; Paick JS; Jang IJ
Br J Clin Pharmacol; 2008 Jun; 65(6):848-54. PubMed ID: 18318773
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study.
Tsuda Y; Ugai H; Wunderlich G; Shin JG
Clin Ther; 2019 May; 41(5):961-971. PubMed ID: 31005336
[TBL] [Abstract][Full Text] [Related]
9. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
10. The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study.
Müller F; Sand M; Wunderlich G; Link J; Schultheis C; Dansirikul C; Sane R; Laszlo R; Steinacker JM
Eur J Clin Pharmacol; 2022 May; 78(5):801-812. PubMed ID: 35089373
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Brown D; Nakagome K; Cordes J; Brenner R; Gründer G; Keefe RSE; Riesenberg R; Walling DP; Daniels K; Wang L; McGinniss J; Sand M
Schizophr Bull; 2019 Mar; 45(2):350-359. PubMed ID: 29718385
[TBL] [Abstract][Full Text] [Related]
12. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
Sidharta PN; Melchior M; Kankam MK; Dingemanse J
Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects.
Hanrahan JP; Wakefield JD; Wilson PJ; Mihova M; Chickering JG; Ruff D; Hall M; Milne GT; Currie MG; Profy AT
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):564-575. PubMed ID: 30422390
[TBL] [Abstract][Full Text] [Related]
14. Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
Singh RSP; Pradhan V; Roberts ES; Scaramozza M; Kieras E; Gale JD; Peeva E; Vincent MS; Banerjee A; Fensome A; Dowty ME; Winkle P; Tehlirian C
Clin Transl Sci; 2021 Mar; 14(2):671-682. PubMed ID: 33290616
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study.
Zhao X; Sheng XY; Payne CD; Zhang X; Wang F; Cui YM
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):952-960. PubMed ID: 32945153
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events.
Goldsmith P; Affinito J; McCue M; Tsai M; Roepcke S; Xie J; Gertsik L; Macek TA
Drugs R D; 2017 Dec; 17(4):631-643. PubMed ID: 29103081
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.
Tsai M; Chrones L; Xie J; Gevorkyan H; Macek TA
Psychopharmacology (Berl); 2016 Oct; 233(21-22):3787-3795. PubMed ID: 27572830
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study.
Zhu X; Wu M; Wang H; Li H; Lin J; Peng Y; Hu Y; Li C; Ding Y
Expert Opin Investig Drugs; 2021 May; 30(5):579-589. PubMed ID: 33682556
[No Abstract] [Full Text] [Related]
20. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]